Home | Publications | Diseases place holder
place holder place holder

Diseases

Global Endocrine Pharmaceutical Market 2005, The

2nd Edition

Publication Date   March 2005
Publisher   Visiongain
Product Type   Report
Pages   170
ISBN Number   not applicable
Product Code   VIS012
Ask a question about this product?

Price £1,499.00

approximately: $2,801 | €1,901

Summary


Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the client will receive an email with information on accessing their purchase.

Visiongain values the total global endocrine market at $43.2bn in 2005, a growth of 13.5% from 2004. The endocrine diseases market is expected to grow over 100% over the forecast period, to produce revenues in 2010 of just under $70bn. Major changes of the market are expected over the forecast period, such as the arrival of insulin delivery technologies and massive losses of the hypothyroidism market due to increasing generic competition.

Designed as an essential business aid, Endocrine 2005 provides a thorough evaluation of the market for you to keep ahead of your competitors.

Learn about the four therapeutic area major earners of the industry:

  • 1) Hypertension
  • 2) Diabetes
  • 3) Osteoporosis
  • 4) Infertility

In addition, Endocrine 2005 also features market analysis of the following:

  • Growth Hormone Replacement
  • Acromegaly

Hypothyrodism and Hyperthyrodism

This 170+ paged report features 50+ tables, 20+ graphs and 20+ charts, news, insights, the very latest developments and an in-depth review of the endocrine market with up to date analysis. This report is a vital addition to gaining an understanding of this lucrative area of the pharmaceutical market, and will give your company 'the edge' of your competitors.

Content


  • 1. Executive Summary
    • 1.1 Report Parameters
    • 1.2 The Endocrine System and Disease
    • 1.3 The Endocrine Glands of the Body
    • 1.4 The Hypothalamus and the Anterior Pituitary
    • 1.5 The Hypothalamus and the Posterior Pituitary
    • 1.6 The Endocrine System
    • 1.7 The Effects of Hormones
    • 1.8 Types of Hormones
    • 1.9 Mechanism of Action
    • 1.10 Control of Hormone Secretion
    • 1.11 Negative Feedback
    • 1.12 Positive Feedback
    • 1.13 Diseases of the Endocrine System
  • 2. The Global Endocrine Disease Market
    • 2.1 2005 Global Endocrine Market Valued at $19.9bn
    • 2.2 Endocrine Disease Winners & Losers
    • 2.3 Endocrine Market Drivers
    • 2.4 Endocrine Market Restraints
    • 2.5 Hypertension
    • 2.6 Osteoporosis
    • 2.7 Diabetes
    • 2.8 Growth Hormone Replacement
    • 2.9 Infertility
    • 2.10 Acromegaly
    • 2.11 Hypothyroidism
    • 2.12 Endocrine Market by Worldwide Region
  • 3. The Global Pituitary Disease Market
    • 3.1 The Posterior Pituitary
    • 3.2 Undersecetion of Vasopressin
    • 3.3 The Anterior Pituitary
    • 3.4 Oversecretion of Pituitray Hormones
    • 3.5 Undersecretion of Pituitary Hormones
    • 3.6 Growth Hormone (GH)
    • 3.7 Effects of GH Secreting Tumours
    • 3.8 Hyposecretion of Growth Hormone
    • 3.9 The World Market for Pituitary Disease Pharmaceuticals
    • 3.10 Sandostatin and Trovert Go Head-to Head
    • 3.11 Acromegaly Market Share: The Fall of Sandostatin
    • 3.12 Acromegaly Market Set to Become a Blockbuster
    • 3.13 Acromegaly Drivers
    • 3.14 Acromegaly Restraints
    • 3.15 Acromegaly Pipeline, 2005
    • 3.16 Genotropin Leads the GH Replacement Market Despite Fall in Sales
    • 3.17 Novo Nordisk's Products Drive GH Replacement Market
    • 3.18 GH Replacement Drugs Revenues Forecast to Grow Well
    • 3.19 GH Replacement Market Drivers
    • 3.20 GH Replacement Market Restraints
    • 3.21GH Replacement Pipeline Portfolio, 2005
  • 4. The Global Hypertensive Market
    • 4.1 Introduction to Hypertension
    • 4.2 Compensatory Mechanisms for Regulating Blood Pressure
    • 4.3 The Renin-Angiotensin System
    • 4.4 Regulation of the Renin-Angiotensin II System
    • 4.5 The Clinical Treatment of Hypertension
    • 4.6 Calcium Channel Blockers
    • 4.7 Angiotensin II Receptor Blockers (ARBs)
    • 4.8 Diuretics
    • 4.9 Beta-Blockers
    • 4.10 Angiotensin-Converting Enzyme (ACE) Inhibitors
    • 4.11 Antihypertensive Therapy with ACE Inhibitors
    • 4.12 Combined Antihypertensive Treatments
    • 4.13 Enalapril (Vasotec)
    • 4.14 The Market for Anti-Hypertensive Drugs
    • 4.15 Pfizer Reigns the Hypertensive Market
    • 4.16 ARB's Are the Highest Earners
    • 4.17 Diovan and Co-Diovan: Fastest Growing Hypertensives
    • 4.18 Cozaar and Hyzaar: World Class Hypertensives from Merck
    • 4.19 ARB Future Looks Good
    • 4.20 Will Norvasc Continue to Dominate the Antihypertensive Market?
    • 4.21 The World Market for Angiotensin II Enzyme Inhibitors and Antagonists
    • 4.22 Total Global Endocrine Hypertensive Market Expected to Clear $3.5bn
    • 4.23 Total Global ARB Market Has High Expectations
    • 4.24 ACE Market Will Lose Out to ARBs
    • 4.25 Drivers of Hypertensive Market
    • 4.26 Restraints of Hypertensive Markets
    • 4.27 Hypertensive Pipeline Portfolio, 2005
  • 5. The Global Diabetes Market
    • 5.1 Introduction to Diabetes
    • 5.2 The Biology of Diabetes Mellitus
    • 5.3 Diabetes Mellitus Type 1
    • 5.4 Diabetes Mellitus Type 2
    • 5.5 Gestational Diabetes
    • 5.6 Maturity- Onset Diabetes in Youth
    • 5.7 Secondary Diabetes
    • 5.8 The Pharmaceutical Treatment of Diabetes
      • 5.8.1 Insulin Analogues
      • 5.8.2 Insulin Sensitising Drugs
      • 5.8.3 Alpha-Glucosidase Inhibitors
      • 5.8.4 Sulfonylureas
      • 5.8.5 Repaglinide
    • 5.9 Two Diabetes Blockbusters Gained in 2003
    • 5.10 Thiazolidinediones: The Leading Diabetic Therapeutics, 2003
    • 5.11 Diabetes Company Winners and Losers
    • 5.12 The Saturated Insulin Market of 2003
    • 5.13 Do Any Currently Marketed Diabetes Drugs Have Blockbuster Potential?
    • 5.14 Novo Nordisk Claims New Product Superior to Lantus
    • 5.15 Aventis's Apidra Similar to Humulog
    • 5.16 Innovative Insulin Delivery Technology: The Race is Hotting Up!
    • 5.17 Implantable Insulin Pumps
    • 5.18 Insulin Pills
    • 5.19 Transdermal Insulin
    • 5.20 Oral Spray Insulin00-2005
    • 5.21 Inhaled Insulin
    • 5.22 Numerous Potential Blockbusting Diabetes Products Set to Arrive 2005-2007
    • 5.23 Exubera: The Wait Continues
    • 5.24 Oralin: Liquid Aerosol Insulin
    • 5.25 Hexyl-Insulin Monoconjugate (HIM2) 'Nowhere Near Phase III'
    • 5.26 AERx iDMS Earlier Market Launch Expected
    • 5.27 Diabetes Market Set to Soar to $19bn by 2010
    • 5.28 Diabetes Market Drivers
    • 5.29 Diabetes Pipeline is Busy
  • 6. The Global Infertility Market
    • 6.1 Introduction to Infertility
    • 6.2 Rises in Infertility
    • 6.3 Causes of Infertility
    • 6.4 The Endocrine Control of Fertility
    • 6.5 The Female Reproductive System
    • 6.6 The Male Reproductive System
    • 6.7 Feedback Control
    • 6.8 Assisted Reproductive Technologies (ART)
    • 6.9 The Pharmacological Control of Infertility
      • 6.9.1 Clomiphene Citrate
      • 6.9.2 Gonadotrophins (LH/FSH)
      • 6.9.3 GnRH Antagonists
      • 6.9.4 Bromocriptene
    • 6.10 The World Market for the Pharmacological Treatment for Infertility
    • 6.11 Gondatrophins Rule the Infertility Market
    • 6.12 Serono Domainates Infertility Drug Market
    • 6.13 Serono's Luveris: A Reveloutionary New Product
    • 6.14 Infertility Drug Market Potential Value Clears $1.5bn
  • 7. Global Osteoporosis Market
    • 7.1 Introduction to Osteoporosis
    • 7.2 The Importance of Oestrogen
    • 7.3 The Endocrine Control of Bone Metabolism
    • 7.4 Overview to the Pharmaceutical Treatment of Osteoporosis
    • 7.5 Bisphosphonates
    • 7.6 Estrogen and Hormone Replacement Therapy
    • 7.7 Selective Estrogen Receptor Modulator (SERM)
    • 7.8 Calcitonin
    • 7.9 Vitamin D and Calcium Supplements
    • 7.10 Forteo: The Miracle Cure of Osteoporosis?
    • 7.11 The 3 Major Changes of the Osteoporosis Pharmaceutical Market
    • 7.12 The World Market for the Pharmaceutical Treatment for Osteoporosis Lead by Fosamax
    • 7.13 Bisphosphonates: The Leading Class of Osteoportic Drugs, 2003
    • 7.14 Merck: The Leading Osteoporosis Company, 2003
    • 7.15 Osteoporosis Global Market is Worth $7.6bn in 2005
    • 7.16 PTH/Anabolic Agents Will Dominate the 2010 Osteoporosis Market
    • 7.17 SERMs Also Expected to Perform Well
    • 7.18 Bisphosphonates Will Suffer Due To Fosamax's Patency-Expiry
    • 7.19 Osteoporosis Market Drivers
    • 7.20 Osteoporosis Market Restraints
    • 7.21 The Women's Health Institute HRT Study
    • 7.22 Osteoporosis Future Developments
  • 8. Global Thyroid Disease Market
    • 8.1 Introduction to the Thyroid Gland
    • 8.2 The Regulation and Function of T3/T4 Secretion
    • 8.3 Hypothyroidism
    • 8.4 Hyperthyroidism
    • 8.5 The Treatments for Hyperthyroidism
    • 8.6 The Pharmaceutical Control of Hyperthyroidism
      • 8.6.1 Tapazole
      • 8.6.2 Propylthiuoracil
    • 8.7 The Rule of Synthroid
    • 8.8 Levoxyl Product Recall Chokes Kings Revenues
    • 8.9 The Generics Are Coming! Low-Cost Versions of Synthroid and Levoxyl are Approved
    • 8.10 Hypothyrodism Revenues Set to Hypo!
    • 8.11 Drivers of the Hypotension Market
    • 8.12 Restraints of the Hypotension Market
    • 8.13 The World Market for the Treatment of Hyperthyroidism
    • 8.14 Drivers of the Hyperthyroidism Market
    • 8.15 Restraints of the Hyperthyroidism Market
  • 9. Global Adrenal Disease Market
    • 9.1 Introduction to Adrenal Glands
    • 9.2 Adrenocortical Control
    • 9.3 The Functions of Cortisol
    • 9.4 The Functions of Aldosterone
    • 9.5 Addison's Disease
    • 9.6 Medrol
    • 9.7 Florinef
    • 9.8 Cushing's Syndrome
    • 9.9 Drug-related Adrenal Insufficiency
    • 9.10 Hyperaldosteronism (Conn's Syndrome)
    • 9.11 Aldactone
    • 9.12 Midamor
    • 9.13 World Market for Adrenocortical Pharmaceuticals
    • 9.14 The World Market for Medrol is Put On-Hold!
  • List of Tables
    • Table 1.1: The Global Endocrine Diseases Market, 2003-2010
    • Table 1.2: The Endocrine System
    • Table 1.3: Endocrine Diseases
    • Table 2.1: Global Forecast Revenues ($m) for the Endocrine Disease Market, 2003-2010
    • Table 2.2: Changes in Market Share (%) Between 2003 and 2010 of the Major Endocrine Disease Markets
    • Table 2.3: Global Revenues ($m) 2003 and 2010 for all Endocrine Diseases
    • Table 2.4: Global Revenues ($m) and Growth Rates (%) for the Pharmaceutical Treatment of Endocrine Disease, 2004
    • Table 2.5: Global Revenues, 2003 and 2010, for the Main Pharmaceutical Treatment Areas of Endocrine Disease
    • Table 2.6: Global Revenue ($m) by Country Region, 2004
    • Table 3.1: The Hormones Secreted by the Anterior Pituitary
    • Table 3.2: Global Revenues ($m) for Sandostatin, 2002 and 2003
    • Table 3.3: The 2003 Global Acromegaly Market: Revenues and Market Share by Drug
    • Table 3.4: The 2010 Global Acromegaly Market: Revenues and Market Share by Drug
    • Table 3.5: World Acromegaly Market Revenue Forecast by Drug, 2003-2010
    • Table 3.6: Acromegaly Pipeline Portfolio, 2005
    • Table 3.7: Global Market Revenues ($m) for GH Replacement Drugs, 2002 & 2003
    • Table 3.8: Global GH Replacement Drugs Market Share, 2002 & 2003
    • Table 3.9: Global Forecast Revenues ($m) and Growth Rates (%) for GH Replacement Drugs, 2003-2010
    • Table 3.10: Growth Hormone Replacement Drug Pipeline Portfolio, 2005
    • Table 4.1: The Global Market for Hypertension Drugs, 2003
    • Table 4.2, The Global Market for Hypertensive Drugs by Company, 2003
    • Table 4.3, Global Market Share for Hypertensive Drugs, 2003
    • Table 4.4: Endocrine Controlled Hypertensives Market, 2003
    • Table 4.5: Total Endocrine Hypertensive Drug Market Forecast ($m) by Class, 2003-2010
    • Table 4.6: Hypertensive Pipeline Products in Late Developmental Stages, 2005
    • Table 5.1: Global Market ($m) and Growth Rates for Diabetes Drugs, 2003
    • Table 5.2: The Global Market ($m) for Diabetic Drugs by Class, 2002 & 2003
    • Table 5.3: The Global Market ($m) for Diabetic Drugs by Company, 2002 & 2003
    • Table 5.4: Oral and Human Insulin Diabetes Drugs Market Share (%), 2002 & 2003
    • Table 5.5: 2005-2007 Pipeline Diabetes Drugs with Blockbuster Potential
    • Table 5.6: Total Global Diabetes Market Revenue (Sm) Forecast for Insulins & Oral AntiDiabetic Drugs, 2003-2010
    • Table 5.7: Late-Stage Development Diabetes Pipeline Product Portfoilo, 2005
    • Table 6.1: Global Infertility Drug Market ($m) and Growth Rate (%), 2002 & 2003
    • Table 6.2: Serono's Infertility Drug Portfolio Performance, 2003 and 2004
    • Table 6.3: Total Global Infertility Drug Market Revenue ($m), 2002 & 2003
    • Table 6.4: Global Market Share (%) by Fertility Drug Class, 2002 & 2003
    • Table 6.5: Global MarketShare (%) by Company, 2003
    • Table 6.6: Total Global Inertility Drug Market Revenue Forecast ($m), 2003-2010
    • Table 6.7: Global Infertility Drug Market Revenue Forecast ($m), 2003-2010 by Class
    • Table 6.8: Infertility Pharmaceutical Pipeline Portfolio, 2005
    • Table 7.1: Global Market ($m) and Growth Rates for Osteoporoitic Drugs, 2003
    • Table 7.2: The Global Market ($m) for Osteoporosis Drugs by Drug Type, 2002 & 2003
    • Table 7.3: Osteoporosis Company Market Share by Revenue ($m), 2002 & 2003
    • Table 7.4: Total Global Osteoporosis Drug Market Revenue Forecast ($m), 2003-2010
    • Table 7.5: Total Global Osteoporosis Market Revenue ($m) By Drug Class, 2003-2010
    • Table 7.6: Osteoporosis Pipeline Product Portfolio, 2005
    • Table 8.1: Hypothyrodism Drug Products Available, 2005
    • Table 8.2: Hypothyrodism Market Revenues ($m), 2002 & 2003 by Drug
    • Table 8.3: Hypothyrodism Market Share (%) 2002 & 2003 by Drug
    • Table 8.4: Global Forecast for Revenue ($m) Growth of the Hypothyroid Market, 2003-2010
    • Table 8.5: Global Revenues ($m) for the Hyperhyroid Market, 2004
    • Table 9.1 Indications of Medrol, 2005
    • Table 9.2: Adrenocortical Pharmaceuticals, 2005
  • List of Graphs
    • Graph 1.1: Total Global Endocrine Market Revenues ($bn), 2003-2010
    • Graph 1.2: Total Global Endocrine Market Growth (%), 2004-2010
    • Graph 2.1: Total Endocrine Pharmaceutical Market Revenue ($m) Forecast by Diease, 2003-2010
    • Graph 2.2 Endocrine Therapeutic Area Revenues ($m), 2003 & 2010
    • Graph 3.1: Total Acromegaly Market Revenue ($m) Forecast 2003-2010 by Drug
    • Graph 3.2: Total Acromegaly Market Revenue ($m) Forecast 2003-2010
    • Graph 3.3: Total Acromegaly Market Revenue Change (%) Forecast 2003- 2010
    • Graph 3.4: Total World GH Replacement Drug Market Revenue Forecast ($m), 2003-2010
    • Graph 3.5: Total World GH Replacement Drug Market Revenue Change Forecast (%), 2003-2010
    • Graph 4.1: World Endocrine Hypertensive Drug Market Revenue ($m) by Class, 2003-2010
    • Graph 4.2: Total World Endocrine Hypertensive Drug Market Revenue ($m), 2003-2010
    • Graph 4.3: Total World Endocrine Hypertensive Drug Market Revenue Growth (%), 2004-2010
    • Graph 5.1: Total Global Diabetes Market Revenue (Sbn) Forecast, 2003- 2010
    • Graph 5.2: Total Global Diabetes Market Growth (%) Forecast, 2003-2010
    • Graph 5.3: Total Global Diabetes Market Revenue Forecast ($m), for Insulins and Oral Anti-Diabetes Drugs, 2003-2010
    • Graph 6.1: Total Global Infertility Drug Market Revenue Forecast ($m), 2003-2010
    • Graph 6.2: Total Global Infertility Drug Market Growth Forecast (%), 2003-2010
    • Graph 6.3: Global Infertility Drug Market Revenue Forecast ($m), 2003-2010 by Class
    • Graph 7.1: Total Global Osteoporosis Market Revenue ($m), 2003-2010
    • Graph 7.2: Total Global Osteoporosis Market Revenue Growth (%), 2003-2010
    • Graph 7.3: Total Global Osteoporosis Market Revenue ($m) By Drug Class, 2003-2010
    • Graph 8.1: Total Global Hypotension Market Revenue ($m), 2003-2010
    • Graph 8.2: Total Global Hypotension Market Revenue Loss (%), 2003-2010
  • List of Charts
    • Chart 2.1: Total Global Endocrine Market Share (%) by Disease, 2003
    • Chart 2.2: Total Global Endocrine Market Share (%) by Disease, 2010
    • Chart 2.3: Global Endocrine Market Share (%) by Country Region, 2004
    • Chart 3.1: Acromegaly Market Share %, 2003
    • Chart 3.2: Acromegaly Market Share %, 2010
    • Chart 3.3: GH Replacement Drugs Market Share (%), 2002
    • Chart 3.4: GH Replacement Drugs Market Share (%), 2003
    • Chart 4.1: Hypertensive Market Share by Company, 2003
    • Chart 4.2: Hypertensive Market Share by Drug Class, 2003
    • Chart 5.1: Diabetes Market Share by Drug Class, 2002
    • Chart 5.2: Diabetes Market Share by Drug Class, 2003
    • Chart 5.3: Diabetes Market Share by Company, 2002
    • Chart 6.1: Global Fertility Drug Market Share (%) by Drug Class, 2002
    • Chart 6.2: Global Fertility Drug Market Share (%) by Drug Class, 2003
    • Chart 6.3: Global Fertility Drug Market Share (%) by Company,
    • Chart 6.4: Global Infertility Drug Market Share (%) by Class, 2010
    • Chart 7.1: Total Osteoporotic Market Share (%) by Drug Class, 2002
    • Chart 7.2: Total Osteoporotic Market Share (%) by Drug Class, 2003
    • Chart 7.3: Total Osteoporotic Company Market Share (%), 2002
    • Chart 7.4: Total Osteoporotic Company Market Share (%), 2003
    • Chart 8.1: Hypothyrodism Market Share %, 2002
    • Chart 8.2: Hypothyrodism Market Share %, 2003